protein therapy clinical trial intelligence

An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors

An Open-label, Phase I Clinical Trial of Autologous T Cells Transduced With NY-ESO-1 Antigen-specific High-affinity T Cell Receptors in NY-ESO-1-positive Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Guangzhou FineImmune Biotechnology Co., LTD. in Sarcoma, Lung Cancers, Melanoma. SEO and diligence focus: Super1 TCR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension

Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension is a EARLY_PHASE1 clinical asset sponsored by Amy Arnold in Obesity, Hypertension. SEO and diligence focus: Angiotensin-(1-7), Saline, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia

Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia is a NA clinical asset sponsored by Université Catholique de Louvain in Acute Myeloid Leukemia, Cachexia. SEO and diligence focus: collection of clinical data and biological samples, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation

A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia. SEO and diligence focus: Ipilimumab, Nivolumab, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Biofilm-induced Antimicrobial Resistance RIsk ERadication in Critical Care Central Venous Catheters

Biofilm-induced Antimicrobial Resistance RIsk ERadication in Critical Care Central Venous Catheters is a registry-stage clinical asset sponsored by Centre Hospitalier Universitaire de Nīmes in Catheter-Related Infections, Biofilms, Infection Prevention. SEO and diligence focus: Microbial analysis of catheter biofilm, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered During Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infants

Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered During Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infants is a registry-stage clinical asset sponsored by Emory University in COVID-19. SEO and diligence focus: Licensed or EUA SARS-CoV-2 vaccine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

RibOSE - Effects of Glucose Ingestion During Resistance Exercise Training on Ribosomal Biogenesis in Skeletal Muscle

RibOSE - Effects of Glucose Ingestion During Resistance Exercise Training on Ribosomal Biogenesis in Skeletal Muscle is a NA clinical asset sponsored by Inland Norway University of Applied Sciences in Healthy. SEO and diligence focus: Glucose, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor

Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor is a PHASE1 clinical asset sponsored by Seattle Children's Hospital in B Cell Leukemia. SEO and diligence focus: Autologous CD19 CAR+ EGFTt + T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Molke Oder Casein - Leberfettreduktion Und Stoffwechselverbesserung Durch Schnelle vs. Langsame Proteine (Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins)

Molke Oder Casein - Leberfettreduktion Und Stoffwechselverbesserung Durch Schnelle vs. Langsame Proteine (Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins) is a NA clinical asset sponsored by Charite University, Berlin, Germany in Type2 Diabetes, NAFLD. SEO and diligence focus: protein supplement, placebo supplement, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity.

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity. is a NA clinical asset sponsored by Universidad de Zaragoza in Type 2 Diabetes, Overweight or Obesity, PreDiabetes. SEO and diligence focus: Diet, Diet, Diet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS)

Explorative Trial to Investigate the Safety and Clinical Effects of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) Following Their Intrathecal and Intravenous Administration in Severe Cases of Multiple Sclerosis (MS) is a PHASE1 clinical asset sponsored by Hadassah Medical Organization in Multiple Sclerosis. SEO and diligence focus: Injection of autologous bone marrow derived mesenchymal stem cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Study of In Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis

Study of In Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis is a NA clinical asset sponsored by Assistance Publique - Hôpitaux de Paris in Autosomal Recessive Congenital Ichthyosis, Epidermolytic Ichthyosis. SEO and diligence focus: Biological samples, Skin biopsy, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Shanghai East Hospital in Solid Tumors, Adult. SEO and diligence focus: LCAR-C18S cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia is a PHASE1 clinical asset sponsored by Medical College of Wisconsin in Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia. SEO and diligence focus: CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT)

A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT) is a PHASE1 clinical asset sponsored by Duke University in Hyperglycemia Drug Induced. SEO and diligence focus: REMD-477, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study

Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study is a NA clinical asset sponsored by Skidmore College in Obesity, Insulin Resistance. SEO and diligence focus: Protein whole foods, Protein Resistance Exercise Training, Protein Stretching/Yoga Training, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease

A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer Disease. SEO and diligence focus: V950, ISCOMATRIX™, Placebo to V950, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE

An Open-label Phase I/IIa, Multicentre, Interventional Single-arm Trial of MB-CART19.1 in Patients With Refractory SLE is a PHASE1 clinical asset sponsored by Miltenyi Biomedicine GmbH in SLE - Systemic Lupus Erythematosus. SEO and diligence focus: MB-CART19.1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme

A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme is a PHASE1 clinical asset sponsored by Beijing Sanbo Brain Hospital in Glioblastoma Multiforme. SEO and diligence focus: Anti-PD-L1 CSR T cells, Cyclophosphamide, Fludarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma.

A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma. is a NA clinical asset sponsored by Nanjing Legend Biotech Co. in Relapsed/Refractory Multiple Myeloma(MM). SEO and diligence focus: LCAR- F33S cells intravenous infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults is a PHASE1 clinical asset sponsored by Stanford University in Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma, Pediatric Brain Tumor, Embryonal Tumor With Multilayered Rosettes (ETMR), Pineoblastoma, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, CNS Neuroblastoma, FOXR2-activated. SEO and diligence focus: GPC2-CAR T cells, Fludarabine, Cyclophosphamide, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes

A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes is a PHASE2 clinical asset sponsored by Hanmi Pharmaceutical Company Limited in Obesity. SEO and diligence focus: HM11260C, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Some Biomarkers Underlying in Ischemic Stroke in Chinese Young Adults: a Protocol for a Case-control Clinical Trial

Some Biomarkers Underlying in Ischemic Stroke in Chinese Young Adults: a Protocol for a Case-control Clinical Trial is a registry-stage clinical asset sponsored by Beijing Chao Yang Hospital in Ischemic Stroke. SEO and diligence focus: Ischemic Stroke, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 in Addition to Anti-PD-1 or Anti-PD-L1 Monoclonal Antibody Therapy in Patients With Solid Tumors is a PHASE1 clinical asset sponsored by NEC Bio B.V in Solid Tumor. SEO and diligence focus: NECVAX-NEO1, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Phase 1, Open-label, Three Routes IV, Intratumoral Injections and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-ARTEMIS™2™ T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)

Phase 1, Open-label, Three Routes IV, Intratumoral Injections and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-ARTEMIS™2™ T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC) is a EARLY_PHASE1 clinical asset sponsored by First Affiliated Hospital Xi'an Jiaotong University in Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer. SEO and diligence focus: ET1402L1-ARTEMIS™ T cells -IV, ET1402L1-ARTEMIS™ T cells -intra-hepatic artery, ET1402L1-ARTEMIS™ T cells -Intratumoral Injections, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis

The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Manifestation of Starvation Ketosis and Ketoacidosis in Patients With Nonalcoholic Steatohepatitis is a NA clinical asset sponsored by The Society of Bariatric and Metabolic Surgeons of Kazakhstan in Obesity, Morbid, NASH, Ketosis, Keto Acidosis, Carbohydrate Metabolism Disorder. SEO and diligence focus: Carbohydrate Restriction after a Gastric Bypass, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia

Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences in Safety Issues, Efficiency. SEO and diligence focus: microtransplantation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers

Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers is a PHASE1 clinical asset sponsored by PATH in Diarrhea. SEO and diligence focus: ACE527, dmLT, CeraVacx placebo, H10407 challenge strain, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Randomized, Double-blinded, Active-controlled Phase II Clinical Study to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥12 Years and Previously Unvaccinated

A Randomized, Double-blinded, Active-controlled Phase II Clinical Study to Evaluate the Immunogenicity and Safety of SCTV01C (A Bivalent SARS-CoV-2 Trimeric Spike Protein Vaccine) and SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥12 Years and Previously Unvaccinated is a PHASE2 clinical asset sponsored by Sinocelltech Ltd. in COVID-19, SARS-CoV-2 Infection. SEO and diligence focus: SCTV01C, SCTV01C, SCTV01C, SCTV01E, SCTV01E, SCTV01E, mRNA vaccine manufactured by Pfizer or Moderna, mRNA vaccine manufactured by Pfizer or Moderna, mRNA vaccine manufactured by Pfizer or Moderna, Sinopharm inactivated COVID-19 vaccine, Sinopharm inactivated COVID-19 vaccine, Sinopharm inactivated COVID-19 vaccine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in B Cell Leukemia, B Cell Lymphoma. SEO and diligence focus: UCART019, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome is a PHASE1 clinical asset sponsored by City of Hope Medical Center in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome. SEO and diligence focus: Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens is a PHASE1 clinical asset sponsored by Medigene AG in Acute Myeloid Leukemia. SEO and diligence focus: WT1/PRAME vaccination, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML

Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML is a PHASE3 clinical asset sponsored by Medical Research Council in Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms. SEO and diligence focus: filgrastim, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, tretinoin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

NYSCF Scientific Discovery Biobank

NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

A Study to Optimize Controlled Human Malarial Infection by Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults

Sanaria Inc.'s study aims to optimize controlled human malarial infection (CHMI) using PfSPZ, targeting healthy adults aged 18-45. The successful establishment of a reliable infection model could enhance the development of malaria vaccines and therapeutics, positioning Sanaria favorably in the malaria prevention market. Given the global burden of malaria, particularly in endemic regions, advancements in this area could attract significant interest from public health organizations and potential partnerships with pharmaceutical companies. The study's completion may also provide valuable data for future clinical trials, enhancing Sanaria's competitive edge in the malaria vaccine landscape.

Matched by modality_normalized: protein therapy

A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Muscle-invasive Bladder Cancer

The trial, sponsored by Peking University, aims to evaluate the safety and tolerability of PD-1 knockout engineered T cells in patients with stage IV muscle-invasive bladder cancer. Given the increasing focus on immunotherapy and the potential for PD-1 inhibition to enhance anti-tumor responses, this asset could represent a significant advancement in the treatment of advanced bladder cancer. However, the trial has been withdrawn due to lack of funding, which raises concerns about the viability of further development without securing financial backing. The competitive landscape includes other PD-1/PD-L1 inhibitors currently in various stages of development, necessitating a thorough diligence process to assess market positioning and potential partnerships.

Matched by modality_normalized: protein therapy

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

The clinical trial for QT-019C, a universal allogeneic CAR T-cell therapy targeting CD19 and BCMA, is positioned to address significant unmet needs in the treatment of relapse/refractory autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, and connective tissue disease-associated thrombocytopenia. The trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China, with collaboration from Shanghai Xiniao Biotech Co., Ltd. Given the increasing prevalence of autoimmune diseases and the limitations of current therapies, QT-019C could capture a substantial market share if proven effective. However, the competitive landscape includes established therapies and emerging biologics, necessitating robust efficacy and safety data to differentiate QT-019C. The trial is currently recruiting, with an estimated completion date in January 2029, indicating a long-term investment horizon for stakeholders.

Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

This Phase I trial, sponsored by City of Hope Medical Center, focuses on a novel cellular immunotherapy approach for high-risk intermediate grade B-lineage non-Hodgkin lymphoma (NHL). The use of genetically modified T cells expressing a CD19-specific CAR represents a significant advancement in the treatment of recurrent or high-risk NHL, a market with substantial unmet medical needs. The competitive landscape includes established CAR T-cell therapies, but this trial's focus on central memory T cells may offer improved persistence and efficacy. Given the increasing demand for innovative therapies in oncology, successful outcomes could position the sponsor favorably for future commercialization and partnerships, particularly in the context of expanding CAR T-cell applications.

A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability and Pharmacokinetics of ISU104, a Human Monoclonal Antibody Targeting ErbB3 in Patients With Advanced Solid Tumors

ISU104, a human monoclonal antibody targeting ErbB3, is currently in a Phase I clinical trial aimed at assessing its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors. The trial's dual-part design includes a dose-escalation phase to establish the recommended Phase II dose (RP2D) and a dose-expansion phase focusing on recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Given the increasing interest in targeted therapies for solid tumors, ISU104 could position ISU Abxis Co., Ltd. favorably within a competitive landscape that includes established therapies like cetuximab. The trial's outcomes may provide critical insights into the drug's efficacy and safety profile, influencing future development strategies and potential partnerships.

Matched by modality_normalized: protein therapy

Effect of Soy Protein and Polydextrose on Food Intake in Young Chinese Adult Males

The study conducted by the Singapore Institute of Food and Biotechnology Innovation explores the effects of soy protein and polydextrose on food intake and satiety in a specific demographic (young Chinese males). Given the rising global obesity rates, the findings could have significant implications for weight management products and dietary supplements. The potential market for functional foods that enhance satiety is substantial, particularly in Asia, where soy products are culturally integrated. Competitively, this research may position the sponsor as a leader in the development of innovative dietary solutions targeting obesity and metabolic health. Diligence should focus on the commercial viability of the findings and potential partnerships with food manufacturers or health-focused brands.

Matched by modality_normalized: protein therapy

Safety and Efficacy of Booster Doses of COVID-19 Vaccine in Immunocompromised Patients With a Cancer Diagnosis

The study, sponsored by Montefiore Medical Center, aimed to evaluate the safety and efficacy of COVID-19 vaccine booster doses in immunocompromised cancer patients who did not develop an adequate antibody response after the primary vaccination series. Given the ongoing need for effective vaccination strategies in vulnerable populations, the results could inform future vaccine recommendations and public health policies. The termination of the study due to funding issues and decreased engagement may limit the data available for market analysis, but it highlights the challenges in conducting clinical trials in this demographic. The competitive landscape includes other ongoing studies targeting similar patient populations, which may impact the market positioning of the findings from this trial.

Matched by modality_normalized: protein therapy

A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

The clinical trial, sponsored by Southwest Hospital in China, focuses on the safety and dosage of CD19-targeted CAR T cells for treating relapsed or refractory B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma. Given the increasing demand for innovative therapies in hematological cancers, this trial positions itself in a competitive landscape dominated by established CAR T therapies like Kymriah and Yescarta. The successful demonstration of safety and efficacy could lead to significant market opportunities, especially in regions with high unmet medical needs. The trial's ongoing recruitment phase indicates potential for timely data readouts, which may attract interest from larger biopharma companies for partnerships or acquisitions.

Matched by modality_normalized: protein therapy

Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy

The study, sponsored by the University of Alberta, aims to evaluate the efficacy of immunoglobulin replacement therapy (IRT) in patients experiencing hypogammaglobulinemia (HGG) following CD19-targeted CAR T cell therapy. With a growing market for CAR T therapies and increasing recognition of the complications associated with B cell depletion, this trial addresses a critical unmet need in infection prevention for these patients. The outcomes may inform future guidelines and treatment protocols, potentially enhancing the commercial viability of immunoglobulin products. The competitive landscape includes other immunoglobulin therapies, but the unique focus on CAR T-related HGG may provide a niche market opportunity. Diligence should consider the regulatory landscape for immunoglobulin therapies and the potential for partnerships with CAR T manufacturers.

Matched by modality_normalized: protein therapy

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

The KarMMa-9 trial, sponsored by Celgene (a subsidiary of Bristol-Myers Squibb), aims to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel), a CAR-T cell therapy targeting BCMA, in combination with lenalidomide maintenance therapy versus lenalidomide alone in adult patients with newly diagnosed multiple myeloma (NDMM) who have had a suboptimal response post-autologous stem cell transplantation (ASCT). Given the increasing prevalence of multiple myeloma and the growing demand for innovative therapies, this trial positions ide-cel as a potential market leader in the treatment of NDMM, particularly for patients with limited response to standard therapies. The competitive landscape includes established therapies such as lenalidomide and emerging CAR-T therapies, necessitating a robust demonstration of ide-cel's clinical benefits to secure market share and reimbursement. The trial's outcomes could significantly influence treatment guidelines and patient management strategies in this therapeutic area.

A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma

KTE-C19 (axicabtagene ciloleucel), developed by Kite, a Gilead Company, is positioned as a leading CAR T-cell therapy targeting CD19 for patients with refractory aggressive non-Hodgkin lymphoma (NHL). The completion of this Phase 1/2 study enhances its market readiness, particularly in the context of increasing competition from other CAR T therapies and novel agents in the hematologic malignancy space. The asset's efficacy in a challenging patient population underscores its potential to capture significant market share, especially as treatment paradigms evolve towards personalized and targeted therapies. The long-term follow-up study (KT-US-982-5968) will provide critical data for ongoing market positioning and reimbursement discussions.

Matched by modality_normalized: protein therapy

The Effects of a Daily Intake of Protein From Cod Fillet and Cod Residual Material for 8 Weeks on Serum Lipids and Fatty Acids, Glucose Regulation and Inflammation Markers in Overweight or Obese Adults: A Randomized Controlled Trial.

The study investigates the health effects of cod protein, both from fillet and residual materials, on overweight or obese adults. Given the rising prevalence of obesity and related metabolic disorders, this research could position cod protein as a functional food ingredient with potential applications in dietary supplements and food products targeting cardiovascular health and glucose regulation. The findings may open avenues for partnerships with food manufacturers and health supplement companies, particularly in markets focused on obesity management and chronic disease prevention. The competitive landscape includes other protein sources and dietary interventions, necessitating a clear differentiation based on efficacy and health benefits derived from cod protein.

Matched by modality_normalized: protein therapy

Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention

The study, sponsored by Göteborg University, investigates dietary interventions in diabetic patients with gastroparesis, focusing on the impact of food particle size on gastric emptying and metabolic control. Given the increasing prevalence of diabetes and related gastrointestinal complications, this research addresses a significant unmet medical need. The findings could inform dietary guidelines and therapeutic strategies, potentially leading to market opportunities in dietary supplements and management of diabetic gastroparesis. Competitive implications may arise from similar studies targeting dietary interventions, necessitating a thorough analysis of existing products and clinical evidence in this niche market.

Matched by modality_normalized: protein therapy

Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

The Phase I/II trial conducted by Oslo University Hospital investigates the safety and immunogenicity of a novel mRNA-based dendritic cell vaccine for advanced malignant melanoma. Given the increasing incidence of melanoma and the limited efficacy of current therapies, this approach could address a significant unmet medical need. The competitive landscape includes established immunotherapies such as checkpoint inhibitors and emerging mRNA therapies. Successful outcomes could position this therapy favorably in the melanoma treatment market, which is projected to grow significantly. Diligence should focus on the trial's safety profile, potential for combination therapies, and the regulatory pathway for mRNA-based vaccines.

Matched by modality_normalized: protein therapy

CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia

The CD19/CD20 Dual-CAR-T therapy is positioned to address a significant unmet medical need in the treatment of refractory and relapsed B-cell leukemia, a condition with limited effective treatment options. The single-arm, open-label design of this Phase 1 trial suggests a focus on early safety and efficacy evaluation, which may facilitate rapid development and potential market entry. Given the increasing interest in CAR-T therapies, particularly in hematological malignancies, successful outcomes could enhance competitive positioning against existing therapies such as Kymriah and Yescarta. The collaboration with China Immunotech (Beijing) Biotechnology Co., Ltd. may provide additional resources and expertise, potentially accelerating development timelines. However, the trial's single-center nature may limit generalizability and raise concerns regarding scalability and manufacturing capabilities.

Matched by modality_normalized: protein therapy

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

This clinical trial, sponsored by Washington University School of Medicine, aims to evaluate the efficacy of tirzepatide in treating Crohn's disease, particularly in patients with difficult-to-treat inflammation. The market for Crohn's disease therapies is competitive, with established biologics such as anti-TNF agents and newer therapies like JAK inhibitors and IL-23 inhibitors. Tirzepatide's novel mechanism may provide a differentiated therapeutic option, potentially capturing market share from existing treatments. The trial's success could enhance the commercial viability of tirzepatide in inflammatory bowel disease (IBD) and expand its indications beyond metabolic disorders. Diligence considerations should focus on patient recruitment, regulatory pathways, and potential market access challenges.

Matched by modality_normalized: protein therapy

A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC

The trial, sponsored by Roswell Park Cancer Institute, is currently recruiting patients to evaluate the efficacy of lamivudine in combination with standard chemoimmunotherapy for extensive stage SCLC. Given the high unmet medical need in this indication, particularly due to the rapid development of treatment resistance, successful outcomes could position lamivudine as a valuable adjunct therapy, potentially expanding its market presence beyond antiviral applications. The competitive landscape includes existing chemotherapy and immunotherapy options, with lamivudine offering a novel mechanism to combat resistance. Stakeholders should monitor the trial's progress and outcomes closely, as positive results could lead to strategic partnerships or licensing opportunities.

Matched by modality_normalized: protein therapy

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

The Phase I trial of 90Y-DOTA-anti-CD25 basiliximab, in combination with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI), aims to enhance outcomes for patients with high-risk acute leukemia or myelodysplastic syndrome. Given the high unmet need in this patient population, successful results could position the asset favorably in the hematologic malignancy treatment landscape. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. However, the competitive landscape includes established therapies and emerging agents targeting similar pathways, necessitating a robust differentiation strategy. The trial's focus on a specific patient demographic (age ≥ 60 years or younger with comorbidities) may limit market size but could also streamline regulatory pathways if successful.

CHRONO-NUTRITION INTERVENTIONS FOR IMPROVING SLEEP QUALITY: The Impact of Last Meal Composition and Timing on Sleep Quality Among Medical Residents at Hospitals

The CHRONO-MED trial, sponsored by the University of Jordan, explores the impact of meal composition and timing on sleep quality among medical residents, a demographic known for high stress and irregular schedules. This study addresses a significant unmet need in sleep management, particularly in high-stress professions. If successful, the findings could lead to novel dietary interventions that enhance sleep quality, potentially opening avenues for partnerships with nutritional supplement companies and healthcare providers focused on sleep disorders. The market for sleep aids is substantial, with increasing consumer awareness of the importance of sleep health. Competitive implications include the potential for differentiation in the crowded sleep aid market through evidence-based nutritional strategies.

Matched by modality_normalized: protein therapy

Pilot Study of Intradermal Vaccination of Melanoma Patients With a Fixed Combination of mRNAs Compared to an Individualized Selection After Analysis of Antigen Expression in Tumor Tissue

This pilot study explores an innovative mRNA-based vaccination approach targeting melanoma-associated antigens, which could position the University Hospital Tuebingen as a leader in personalized cancer immunotherapy. The study's completion and the focus on both fixed combinations and individualized antigen selection may provide valuable insights into patient-specific responses, potentially enhancing the therapeutic landscape for advanced melanoma. Given the increasing interest in mRNA technologies, particularly following the success of COVID-19 vaccines, this study could attract attention from biopharmaceutical companies seeking to expand their oncology portfolios. The competitive landscape includes established immunotherapies such as checkpoint inhibitors, necessitating a clear demonstration of efficacy and safety to carve out a market niche.

Matched by modality_normalized: protein therapy

Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The pilot study evaluates CD38-targeted CAR T-cell therapy for relapsed or refractory acute myeloid leukemia (AML), a significant unmet medical need in hematological malignancies. The study's single-center design and open-label nature may limit generalizability but allows for focused data collection. The target population of CD38 positive AML patients presents a niche market opportunity, particularly as existing therapies may not effectively address relapsed cases. Competitive landscape analysis indicates a growing interest in CAR T-cell therapies, with several companies pursuing similar targets. Successful outcomes could position the sponsor favorably for partnerships or licensing agreements, enhancing their portfolio in immuno-oncology.

Matched by modality_normalized: protein therapy

A Phase I/II Study to Evaluate the Safety and Efficacy of Anti-CLL1-CD33-NKG2D Bicephali CAR-T Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The clinical trial sponsored by Xuzhou Medical University aims to evaluate a novel CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML). Given the high unmet medical need in this patient population, successful outcomes could position this therapy as a competitive alternative to existing treatments, potentially capturing significant market share in the CAR-T space. The collaboration with Yake Biotechnology Ltd. may enhance development capabilities and commercialization prospects. However, the trial's not-yet-recruiting status indicates that market entry is still several years away, with estimated completion in 2029. Stakeholders should monitor the evolving landscape of AML therapies and the competitive positioning of this asset as it progresses through clinical development.

Matched by modality_normalized: protein therapy

Ceprotin Treatment Registry

The Ceprotin Treatment Registry, sponsored by Baxalta (now part of Shire), aims to gather comprehensive data on the treatment and safety outcomes of patients with severe congenital Protein C deficiency receiving Ceprotin. Given the rarity of this condition, the registry serves as a critical tool for understanding treatment efficacy and safety, potentially enhancing market positioning for Ceprotin in the niche coagulation disorder space. The completion of this observational study may provide valuable insights for future product development and regulatory submissions, while also reinforcing Shire's commitment to rare disease management. The competitive landscape includes other therapies targeting coagulation disorders, necessitating ongoing vigilance regarding emerging treatments and market entrants.

Matched by modality_normalized: protein therapy

Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors

The trial investigates the combination of CT-011, an anti-PD-1 monoclonal antibody, with a p53 vaccine in patients with advanced solid tumors that have not responded to standard therapies. This combination aims to enhance immune recognition and destruction of cancer cells with p53 mutations. Given the increasing focus on immuno-oncology, successful outcomes could position this therapy favorably in a competitive market, particularly against existing PD-1/PD-L1 inhibitors. However, the trial's withdrawal status raises concerns regarding the feasibility and potential market entry of this combination therapy. Further diligence is required to assess the implications of this withdrawal on ongoing and future development efforts.

Matched by modality_normalized: protein therapy

Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL) Health Promoting Rehabilitation. A Multimodal Exercise-based Intervention in Patients With Acute Leukaemia Undergoing Re-induction or Consolidation Chemotherapy

The PACE-AL trial, sponsored by the Universitetshospitalernes Center for Sygepleje, investigates a multimodal exercise-based intervention aimed at improving the quality of life and physical function of patients undergoing consolidation chemotherapy for acute leukemia. Given the increasing focus on supportive care and rehabilitation in oncology, this study aligns with market trends emphasizing holistic patient management. The collaboration with notable partners such as Novo Nordisk A/S and the Danish Cancer Society enhances credibility and may facilitate future commercialization opportunities. The results could position the intervention as a standard supportive care practice, potentially influencing reimbursement strategies and clinical guidelines.

Matched by modality_normalized: protein therapy

Safety and Effect Assessment of TACE in Combination With Autologous PD-1 Knockout Engineered T Cells by Percutaneous Infusion in the Paitents With Advanced Hepatocellular Carcinoma.

This clinical trial, sponsored by Central South University, investigates the combination of transcatheter arterial chemoembolization (TACE) and PD-1 knockout engineered T cells for the treatment of advanced hepatocellular carcinoma (HCC). The market for HCC therapies is growing due to increasing incidence rates and a lack of effective treatment options for unresectable cases. The innovative approach of combining TACE with genetically modified T cells may provide a competitive edge in the immuno-oncology space, particularly in regions with high HCC prevalence. However, the trial's current status is 'recruiting,' and the overall status remains 'unknown,' indicating potential risks in timelines and regulatory pathways. Diligence should focus on the safety profile and efficacy outcomes as they will significantly influence market entry and adoption.

Matched by modality_normalized: protein therapy

An Open Label, Phase 1 Study Evaluating the Activity of Modular CAR T for mYeloma

The ongoing Phase 1 trial sponsored by University College London is evaluating a novel BCMA CAR T-cell therapy, both as a standalone treatment and in combination with a CD19 CAR, for patients with relapsed/refractory multiple myeloma. The market for multiple myeloma therapies is expanding, with increasing demand for innovative treatments due to the limitations of existing therapies. The dual-targeting approach may provide a competitive edge in efficacy and safety, addressing a significant unmet need in this patient population. The trial's success could position the sponsor favorably for future partnerships or commercialization opportunities, particularly in the context of advanced therapy medicinal products (ATMPs).

Matched by modality_normalized: protein therapy

A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

The clinical trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China and aims to evaluate the safety and preliminary efficacy of universal allogeneic CAR T-cell therapy targeting CD19 and BCMA in patients with relapse/refractory autoimmune diseases. The market for CAR T-cell therapies is expanding, particularly in the context of autoimmune diseases, where current treatment options are limited and often ineffective. The trial's focus on multiple autoimmune conditions, including systemic lupus erythematosus and systemic sclerosis, positions it strategically within a niche but growing segment of the biopharma market. Competitive implications include potential differentiation from existing therapies through the use of allogeneic cells, which may offer advantages in terms of accessibility and scalability. Diligence considerations should include the regulatory landscape in China and potential pathways for global expansion.

Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma

The clinical trial is sponsored by Shanghai Tongji Hospital and aims to evaluate the safety and efficacy of spCART-269 in patients with relapsed or refractory multiple myeloma (MM). Given the increasing prevalence of MM and the limited efficacy of existing therapies, this asset could address a significant unmet medical need. The trial's single-arm design and focus on a specific patient population may streamline regulatory pathways, but the lack of randomization may raise questions regarding comparative efficacy. The competitive landscape includes established therapies such as proteasome inhibitors and immunomodulators, as well as emerging CAR-T therapies targeting other antigens. Successful outcomes could position spCART-269 favorably in the market, particularly if it demonstrates superior safety and efficacy profiles.

Susceptibility to Infections in Patients With Ataxia Telangiectasia : A Prospective Follow-up Study

The study conducted by Johann Wolfgang Goethe University Hospital aims to elucidate the incidence and severity of respiratory infections in patients with Ataxia Telangiectasia (A-T) compared to healthy controls. Given the rarity of severe infections despite immunodeficiency, the findings may influence treatment paradigms regarding immunoglobulin replacement therapy in A-T patients. The collaboration with CSL Behring, a leader in immunotherapy, suggests potential interest in developing targeted therapies or supportive care strategies for A-T. The market for A-T treatments is niche but could expand if new therapeutic approaches are validated. The results may also impact competitive positioning for companies involved in immunotherapy and rare disease management.

Matched by modality_normalized: protein therapy

Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Chongqing Precision Biotech Co., Ltd is advancing a promising CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The market for AML therapies is significant, with a growing demand for innovative treatments due to high relapse rates and limited options for refractory cases. The competitive landscape includes established therapies such as chemotherapy and emerging CAR-T cell therapies. Successful outcomes in this trial could position Chongqing Precision Biotech favorably against competitors, potentially leading to strategic partnerships or acquisition interest. Diligence considerations should focus on regulatory pathways, manufacturing capabilities, and the scalability of CAR-NK cell production.

Matched by modality_normalized: protein therapy

A Phase 1, First-in-Human, Randomized, Observer-blind, Controlled, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Seasonal Influenza Vaccine (ARCT-2138), When Administered to Healthy Adults

Arcturus Therapeutics, Inc. is advancing ARCT-2138, a self-amplifying mRNA vaccine for seasonal influenza, through a Phase 1 clinical trial. This innovative approach leverages mRNA technology, which has gained significant traction due to its success in COVID-19 vaccines. The market for seasonal influenza vaccines is substantial, with ongoing demand for improved efficacy and safety profiles. The competitive landscape includes established players like Seqirus and Sanofi, which may pose challenges. Successful trial outcomes could position Arcturus favorably for partnerships or acquisitions, enhancing its market presence in the vaccine sector.

Matched by modality_normalized: protein therapy

The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis

The trial, sponsored by Yonsei University, investigates the use of autologous BM-MSCs for treating alcoholic liver cirrhosis, a significant unmet medical need given the rising prevalence of liver diseases globally. If successful, this therapy could position itself in a niche market with limited competition, particularly in the context of regenerative medicine for liver conditions. The commercial potential is underscored by the increasing focus on cell-based therapies and the growing demand for innovative treatments in hepatology. Diligence should focus on regulatory pathways, potential reimbursement scenarios, and the scalability of BM-MSC production.

Matched by modality_normalized: protein therapy

A Phase I Clinical Trial of CART Cell Therapy for Refractory/ Relapsed Acute Lymphoblastic Leukemia With Unmet Needs in Children, Adolescents and Young Adults: Feasibility and Safety Study (REALL_CART).

The REALL_CART trial, sponsored by Instituto de Investigación Hospital Universitario La Paz, aims to evaluate the feasibility and safety of two distinct CAR T-cell therapies targeting CD19/CD22 and NKG2D in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Given the high unmet medical need in this patient population, particularly for T-ALL, successful outcomes could position these therapies as significant advancements in the treatment landscape. The trial's focus on academic production of CAR T-cells may also provide a cost-effective alternative to commercial therapies, potentially enhancing market access. The competitive landscape includes established CAR T therapies like Kymriah and Yescarta, which primarily target CD19, indicating a need for differentiation through efficacy and safety profiles. Diligence should focus on the trial's recruitment pace, regulatory pathways, and potential for subsequent commercialization or partnerships.

Peds IMPACT: Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in Newly Diagnosed and Recurrent CD70+ Pediatric High-Grade Gliomas (pHGG) and Diffuse Intrinsic Pontine Glioma (ndDIPG)

The Peds IMPACT trial, sponsored by the University of Florida, aims to evaluate the safety and feasibility of an innovative CAR T cell therapy targeting CD70 in pediatric patients with high-grade gliomas and DIPG. Given the high unmet medical need in pediatric brain tumors, particularly in CD70+ cases, successful outcomes could position this therapy as a leading option in a niche but critical market. The trial's focus on a genetically modified cellular therapy aligns with current trends in oncology towards personalized medicine and immunotherapy. Competitive implications include potential partnerships with larger biopharma companies for further development and commercialization, particularly if early results demonstrate significant efficacy and safety. Diligence considerations should include the regulatory pathway, potential for accelerated approval, and the need for robust clinical data to support market entry.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

VK2735, a dual agonist targeting GLP-1 and GIP receptors, is being evaluated for weight management in obese and overweight adults with comorbid conditions. The obesity treatment market is rapidly expanding, driven by increasing prevalence rates and demand for effective therapies. VK2735's unique mechanism may provide a competitive edge over existing GLP-1 receptor agonists, particularly if it demonstrates superior efficacy and safety profiles. Viking Therapeutics, Inc. should prepare for potential partnerships or licensing opportunities based on trial outcomes, as well as consider strategies for market entry and positioning against established players in the obesity treatment landscape.

Matched by modality_normalized: protein therapy

A Double Blind, Randomized, Placebo Controlled Phase 2b Study to Evaluate the Safety and Clinical Efficacy of Treatment With the Autologous Cell Therapy Product, NG01, in Patients With Secondary Progressive Multiple Sclerosis

NeuroGenesis Ltd. is advancing NG01, an autologous cell therapy, through a Phase 2b clinical trial aimed at addressing unmet needs in SPMS, a progressive form of multiple sclerosis with limited treatment options. The trial's design includes a randomized, double-blind, placebo-controlled approach, which enhances the credibility of potential efficacy claims. If successful, NG01 could capture a significant share of the SPMS market, which is currently underserved. The trial's outcomes may position NeuroGenesis favorably against competitors in the regenerative medicine space, particularly those focusing on neurological disorders. However, the company must navigate the complexities of regulatory approval and reimbursement pathways for cell therapies, which could impact market entry timelines and pricing strategies.

A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 and Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head-Neck Squamous Cell Carcinoma

Nykode Therapeutics ASA is advancing VB10.16, a therapeutic DNA vaccine, in combination with pembrolizumab, a PD-1 inhibitor, for the treatment of unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). This dual approach leverages the established efficacy of pembrolizumab while potentially enhancing immune response through VB10.16. The market for HNSCC treatment is competitive, with several immunotherapies and targeted therapies available. Successful outcomes could position Nykode favorably against existing therapies, particularly if the combination demonstrates superior efficacy or safety profiles. Diligence should focus on the trial's safety and efficacy data, as well as the potential for regulatory pathways and market access strategies, given the increasing emphasis on personalized medicine in oncology.

Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)

The trial, sponsored by the Medical College of Wisconsin, investigates the efficacy of single versus double umbilical cord blood transplantation in pediatric patients with high-risk leukemia and myelodysplasia. Given the increasing prevalence of hematologic malignancies in children and the potential for improved outcomes with double UCB transplants, this study could significantly impact treatment protocols and market dynamics in pediatric oncology. Successful results may enhance the competitive positioning of UCB transplantation as a standard of care, potentially influencing reimbursement policies and attracting interest from biopharma companies focused on hematological therapies.

Matched by modality_normalized: protein therapy

A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)

The clinical trial conducted by Mayo Clinic represents an exploratory approach to ALS treatment through autologous mesenchymal stem cell therapy. Given the progressive nature of ALS and the limited treatment options currently available, this trial could position the sponsor favorably within a niche market focused on neurodegenerative diseases. The successful demonstration of safety and potential efficacy could attract interest from larger biopharmaceutical companies for partnerships or acquisition, especially in light of the growing demand for innovative therapies in ALS. Competitive implications include the need to monitor other ongoing trials in stem cell therapies for ALS, as well as alternative treatment modalities that may emerge. Diligence considerations should focus on the regulatory landscape for stem cell therapies and the potential for reimbursement challenges in the U.S. healthcare system.

Matched by modality_normalized: protein therapy

Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.

The study, sponsored by the University of Nottingham, explores the therapeutic potential of controlled hookworm exposure as a novel immunomodulatory treatment for relapsing forms of Multiple Sclerosis (MS). Given the increasing prevalence of MS in Western populations and the limitations of current disease-modifying therapies, this approach could address an unmet medical need. The market for MS therapies is substantial, with existing treatments generating billions in revenue. However, the unique mechanism of action involving parasitic infection may face regulatory scrutiny and public perception challenges. Competitive analysis indicates that while there are numerous MS therapies, few explore immunomodulation through parasitic mechanisms, potentially positioning this study as a pioneering effort in a niche market. Diligence considerations should focus on safety, tolerability, and the ethical implications of using live parasites in treatment.

Matched by modality_normalized: protein therapy

A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

This clinical trial, sponsored by the First Affiliated Hospital of Sun Yat-Sen University, aims to evaluate the safety and efficacy of TALEN and CRISPR/Cas9 gene editing technologies in treating HPV-related cervical intraepithelial neoplasia (CIN). Given the prevalence of HPV infections and the associated risk of cervical cancer, successful outcomes could position these gene-editing therapies as innovative treatment options in a market with significant unmet needs. The competitive landscape includes traditional HPV treatments and emerging gene therapies, necessitating thorough diligence on regulatory pathways and potential market entry strategies.

Matched by modality_normalized: protein therapy

Phase Ib, Open-Label Study of CART-EGFR-IL13Rα2 Cells Administered Following Lymphodepleting Chemotherapy or Prior to Surgical Resection in Patients With EGFR-Amplified Recurrent Glioblastoma

The University of Pennsylvania is conducting a Phase 1b open-label study to evaluate CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified recurrent glioblastoma. This study aims to explore different dosing strategies, which could provide a competitive edge in the CAR T-cell therapy market, particularly for glioblastoma, a challenging indication with high unmet medical need. The trial's focus on safety, feasibility, and preliminary efficacy may attract interest from potential partners or investors, especially given the limited treatment options available for recurrent glioblastoma. The successful development of this therapy could position the sponsor favorably in the oncology market, which is increasingly leaning towards personalized and targeted therapies.

Matched by modality_normalized: protein therapy

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

The CAR-T therapy targeting CD19 positive B-cell acute lymphocytic leukemia (ALL) represents a significant advancement in the treatment of CNS leukemia, a challenging subset of ALL. Given the high unmet medical need and the limited treatment options available for CNS involvement, this therapy could capture a substantial market share if proven effective. The collaboration with The First Affiliated Hospital of Soochow University may enhance credibility and facilitate patient recruitment. However, the competitive landscape includes established CAR-T therapies, necessitating a focus on differentiating efficacy and safety profiles. Ongoing diligence is required to monitor regulatory pathways and potential market entry timelines, particularly as the trial is currently in the recruiting phase with an estimated completion date in late 2025.

Matched by modality_normalized: protein therapy

Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy

The pilot study of ARI-0001, an autologous T-cell therapy targeting CD19, addresses a significant unmet need in patients with refractory CD19+ leukemia and lymphoma. Given the increasing demand for CAR T-cell therapies, particularly in hematological malignancies, this asset positions itself in a competitive landscape dominated by established players like Novartis and Gilead. The successful completion of this trial could pave the way for further development and potential commercialization, particularly in Europe, where the study is based. The collaboration with Instituto de Salud Carlos III may enhance credibility and facilitate regulatory pathways. However, the market is characterized by rapid innovation, necessitating ongoing diligence on competitive advancements and potential market entry strategies.

Open Label, Single Arm Clinical Trial to Evaluate the Safety and Efficacy of CT0590 Chimeric Antigen Receptor T Cell （CAR T）in Patients With Relapsed and/or Refractory Multiple Myeloma

CT0590 is positioned within the competitive landscape of CAR T therapies for relapsed and/or refractory multiple myeloma, a market with significant unmet needs and growing demand for innovative treatments. The trial, sponsored by The First Affiliated Hospital of Soochow University in collaboration with CARsgen Therapeutics, aims to establish the safety and efficacy of CT0590, which could potentially capture market share in a sector dominated by established therapies such as Bristol-Myers Squibb's Abecma and GSK's Blenrep. The successful completion of this trial could enhance the commercial viability of CT0590, especially if it demonstrates superior efficacy or a favorable safety profile compared to existing options. The estimated enrollment of 24 patients indicates a focused approach, which may facilitate quicker data readouts and regulatory interactions.

Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study

The study, sponsored by Fondation Hôpital Saint-Joseph, aims to evaluate the venous thrombotic biological profile across various PCOS phenotypes, addressing a significant gap in understanding the cardiovascular risks associated with PCOS. With PCOS being the most prevalent endocrine disorder among women of childbearing age, the findings could lead to improved clinical management and personalized treatment strategies, potentially enhancing the market for diagnostic tests and therapeutic interventions targeting PCOS. The competitive landscape may include other diagnostic and therapeutic entities focused on PCOS and related cardiovascular risks, necessitating thorough diligence to identify potential partnerships or acquisition targets.

Matched by modality_normalized: protein therapy

Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer

The trial evaluates the combination of cabozantinib and panitumumab in KRAS wild-type metastatic colorectal cancer (CRC) and cabozantinib monotherapy in MET amplified CRC. Given the high unmet need in treatment-refractory CRC, successful outcomes could position this combination as a competitive option in the oncology market. The trial's completion in 2018 suggests that data may be available for further analysis, which could influence strategic partnerships or acquisitions in the oncology space. The involvement of Exelixis indicates potential commercial interest in the cabozantinib franchise, which could enhance market positioning if results are favorable.

Matched by modality_normalized: protein therapy

A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid

The T-FLAG regimen, combining topotecan, fludarabine, cytarabine, and G-CSF, targets patients with poor prognosis acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and relapsed/refractory acute lymphocytic leukemia (ALL). Given the high unmet medical need in these indications, successful outcomes could position this therapy favorably in a competitive market, particularly against existing therapies such as standard chemotherapy and newer agents. The study's completion in 2004 suggests that further analysis of the results could inform potential licensing opportunities or partnerships for commercialization. The market for AML and MDS therapies is significant, with ongoing demand for innovative treatment options.

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies

This clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, aims to evaluate the efficacy of Cord Blood Transplantation (CBT) in children and young adults with high-risk hematologic malignancies. The study is currently recruiting participants, indicating a proactive approach to addressing a significant unmet medical need in this demographic. The potential success of CBT could position Memorial Sloan Kettering as a leader in pediatric hematologic oncology, enhancing its reputation and attracting further funding and partnerships. The market for hematologic malignancies is substantial, with increasing demand for innovative therapies, particularly in the pediatric segment. Competitive implications include the need to monitor other emerging therapies in the space, such as CAR-T cell therapies and other transplant modalities, which may pose challenges or opportunities for collaboration.

Matched by modality_normalized: protein therapy

Post-transfusion Platelet Count

The study, sponsored by Region Skane, aimed to elucidate the effects of platelet transfusion on platelet counts and associated biomarkers in hematological patients. Given the increasing demand for platelet transfusions in oncology and hematology, understanding the dynamics of platelet count post-transfusion could enhance clinical practices and patient outcomes. The findings may inform product development strategies for transfusion-related therapies and diagnostics, potentially positioning Region Skane as a key player in this niche market. Furthermore, insights gained could lead to collaborations with biopharmaceutical companies focusing on hematological conditions, thereby enhancing competitive positioning in the market. Diligence implications include assessing the potential for commercialization of any novel biomarkers identified during the study.

Matched by modality_normalized: protein therapy

A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)

Brainstorm Cell Therapeutics is advancing its investigational product, NurOwn (Debamestrocel), through a Phase 3b trial targeting early symptomatic and moderate presentation of Amyotrophic Lateral Sclerosis (ALS). The trial's dual-part design, including a randomized placebo-controlled phase followed by an open-label extension, aims to establish both efficacy and safety. If successful, NurOwn could capture a significant share of the ALS treatment market, which is currently limited in options. The competitive landscape includes other therapies in development, but few focus on stem cell-based approaches. The trial's outcomes will be critical for investor confidence and potential partnerships, especially given the unmet medical need in ALS.

Safety and Tolerability of the Ketogenic Diet in ALS

The trial, sponsored by Johns Hopkins University, aimed to evaluate the safety and tolerability of the ketogenic diet in ALS patients with gastrostomy tubes. Although the study has been terminated, it highlights the growing interest in dietary interventions for neurodegenerative diseases, particularly ALS. The market for ALS treatments is competitive, with existing therapies like Riluzole and emerging gene therapies. Companies exploring dietary supplements or nutritional interventions may find strategic opportunities, especially if safety data supports further investigation. Diligence should focus on the regulatory landscape surrounding dietary supplements and the potential for partnerships with academic institutions.

Matched by modality_normalized: protein therapy

A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma

The trial, sponsored by Peking University, aims to evaluate the safety of PD-1 knockout engineered T cells in patients with metastatic renal cell carcinoma (RCC) who have progressed after standard treatments. Given the increasing interest in immunotherapies and CAR-T cell therapies, this asset could represent a novel approach in a competitive landscape dominated by existing therapies such as checkpoint inhibitors. However, the trial has been withdrawn due to lack of funding, which raises concerns about the viability of further development and potential market entry. The RCC market is projected to grow, driven by advancements in immunotherapy, but the absence of funding may hinder this asset's progress.

Matched by modality_normalized: protein therapy

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma

Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary Central Nervous System (CNS) Lymphoma is a PHASE1 clinical asset sponsored by University College, London in Primary CNS Lymphoma. SEO and diligence focus: CD19CAR T-cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: protein therapy

Phase I Dose Escalation Trial of CD19 Directed Chimeric Antigen Receptor T Cell Therapy in the Treatment of Relapsed/Refractory B Cell Malignancies

The Phase I trial of IC19/1563, a CD19-directed CAR-T cell therapy, is being conducted by the Mayo Clinic to address the unmet medical need in relapsed/refractory B cell malignancies. Given the increasing prevalence of B cell malignancies and the limitations of existing therapies, this trial could position IC19/1563 as a competitive alternative in the CAR-T therapy market. The trial's focus on in-house, point-of-care manufacturing may enhance accessibility and reduce costs compared to existing CAR-T therapies, which are often associated with complex logistics and high pricing. The successful demonstration of safety and efficacy could lead to significant market opportunities, especially as the demand for personalized cancer therapies continues to rise.

Matched by modality_normalized: protein therapy

A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

The CAR-37 T Cell therapy is positioned to address a significant unmet need in the treatment of relapsed or refractory CD37+ hematologic malignancies, including various forms of lymphoma and leukemia. Given the complexity of the target patient population, which has limited treatment options after multiple lines of therapy, CAR-37 T Cells could capture a niche market within the CAR-T cell therapy landscape. The competitive landscape includes established CAR-T therapies targeting CD19 and BCMA, but CAR-37's unique targeting of CD37 may provide a differentiated therapeutic option. The completion of this Phase 1 trial will be critical for advancing to later stages of development and potential commercialization, contingent on safety and efficacy results. Investors and stakeholders should monitor the trial outcomes closely, as they will inform the asset's viability and market entry strategy.

Matched by modality_normalized: protein therapy

A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)

The Phase I trial of the Survivin long peptide vaccine (SurVaxM) is sponsored by Roswell Park Cancer Institute and focuses on patients with metastatic neuroendocrine tumors (NETs). Given the limited treatment options for advanced NETs, this vaccine could represent a novel immunotherapeutic approach, potentially enhancing the immune response against tumors expressing survivin. The market for NET therapies is growing, with increasing incidence rates and a demand for innovative treatments. Competitive analysis indicates that while somatostatin analogs are standard care, there is a gap for immunotherapies, positioning SurVaxM favorably. Diligence should focus on safety and efficacy data as well as potential partnerships for further development and commercialization.

Matched by modality_normalized: protein therapy

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

This Phase II trial, sponsored by the National Cancer Institute, investigates the efficacy of neoadjuvant chemotherapy regimens in hormone receptor-poor/HER2-negative breast cancer, a segment with significant unmet medical need. The inclusion of carboplatin and bevacizumab may enhance pathologic complete response rates, potentially positioning these combinations as competitive options in the neoadjuvant setting. The results could influence treatment guidelines and market dynamics, particularly for therapies targeting this specific breast cancer subtype. Companies involved in breast cancer therapeutics should monitor outcomes closely for potential shifts in standard of care and consider implications for their own product pipelines.

Matched by modality_normalized: protein therapy

A Phase IIIb, Open, Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine Administered on a 0-6 Mth Schedule Concomitantly With Wyeth Lederle's Pneumococcal Conjugate Vaccine in Healthy Children 15 Months of Age

The Phase IIIb trial conducted by GlaxoSmithKline (GSK) evaluates the immunogenicity and safety of the inactivated hepatitis A vaccine (Havrix) when co-administered with Wyeth Lederle's pneumococcal conjugate vaccine (Prevnar) in children aged 15 months. The study's completion in January 2006 positions GSK to leverage the findings for market expansion in pediatric vaccination, particularly in regions with high hepatitis A incidence. The dual vaccination approach may enhance market competitiveness against standalone vaccines, potentially increasing GSK's share in the pediatric vaccine market. The successful demonstration of non-inferiority in seropositivity rates could facilitate broader adoption in immunization schedules, impacting public health initiatives and vaccine procurement strategies.

Matched by modality_normalized: protein therapy

Effects of Milk Protein Intake in Young Children on Early Growth and Later Obesity Risk: a Multicentre Randomized Clinical Trial

The Toddler Milk Intervention Trial (ToMI), sponsored by Société des Produits Nestlé, aims to evaluate the impact of varying protein content in young-child formulas on growth and obesity risk in children aged 11.5 to 13.5 months. Given the increasing global concern over childhood obesity, this trial addresses a significant market need for nutritional products that promote healthy growth. The results could enhance Nestlé's portfolio in pediatric nutrition, potentially leading to competitive advantages in the infant formula market. The study's completion in 2024 positions Nestlé to leverage findings for product development and marketing strategies targeting health-conscious parents. The trial's multicenter design across Germany and Spain may also facilitate broader European market penetration.

Matched by modality_normalized: protein therapy

Thioredoxin Reductase 1 Levels in Gingival Tissue as an Oxidative Stress Biomarker in Periodontitis

This observational study conducted by Ataturk University focuses on the role of TrxR1 as a potential biomarker for periodontitis. Given the increasing prevalence of periodontal diseases and the growing demand for effective diagnostic tools, the findings could position TrxR1 as a valuable asset in the dental and pharmaceutical markets. The study's results may lead to the development of novel diagnostic assays or therapeutic interventions targeting oxidative stress in periodontal disease, presenting opportunities for partnerships or licensing agreements. The competitive landscape includes existing biomarkers for periodontitis, but TrxR1's specificity could provide a differentiated offering. Diligence should consider the regulatory pathway for any resulting diagnostic products and the potential for patent protection around TrxR1-related methodologies.

Matched by modality_normalized: protein therapy

A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne

Naked Biome, Inc. is exploring a novel approach to acne treatment through the application of NB01, a live strain of P. acnes, aimed at restoring skin microbiome balance. The acne treatment market is substantial, with a growing demand for innovative therapies that address the limitations of current options, such as antibiotics and retinoids. The unique mechanism of action of NB01 may position it favorably against existing therapies, particularly in the context of rising antibiotic resistance. Successful outcomes could lead to significant market penetration, especially among younger demographics aged 13-40, who are the primary sufferers of acne. The competitive landscape includes traditional topical treatments and emerging microbiome-based therapies, necessitating thorough diligence on clinical efficacy and safety profiles to ensure differentiation.

Matched by modality_normalized: protein therapy

Prospective, Multicenter, Open, One-arm Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

The clinical trial is sponsored by The Affiliated Hospital of Xuzhou Medical University and aims to evaluate the safety and efficacy of a combination regimen of BTK inhibitors and Anti-CD19 CAR-T cells in patients with relapsed/refractory B-cell Non-Hodgkin Lymphoma (B-NHL). Given the increasing prevalence of B-NHL and the limitations of current treatment options, this study addresses a significant unmet medical need. If successful, the results could position the combination therapy as a competitive option in the oncology market, particularly against existing therapies such as monoclonal antibodies and other CAR-T cell therapies. The trial's outcomes may also influence market dynamics and investor interest in CAR-T and BTK inhibitor technologies.

Matched by modality_normalized: protein therapy

Phase 1 Study: Induction of Systemic Immune Responses in Metastatic Breast Cancer Patients by Vaccination With a CD80-modified, Devitalized HLA-*A0201+ Breast Cancer Cell Line (KS24.22)

The Phase 1 trial conducted by University Hospital Tuebingen aims to evaluate the safety and feasibility of a novel immunotherapy approach using a genetically modified allogeneic breast cancer cell line. Given the increasing focus on personalized and targeted therapies in oncology, this study positions itself within a competitive landscape that includes other immunotherapeutic strategies for metastatic breast cancer. The successful demonstration of safety and immunogenicity could pave the way for further development and potential partnerships or licensing opportunities, particularly as the market for breast cancer therapies continues to expand. However, the trial's completion in 2010 suggests that further development may hinge on subsequent studies and data analysis to establish a clear therapeutic advantage over existing treatments.

Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study

KD6001 is being evaluated for its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors, particularly those who have failed standard treatments. The market for advanced solid tumor therapies is significant, with increasing demand for innovative treatments, especially in oncology. Given the competitive landscape, where numerous therapies are vying for approval, KD6001's unique profile and the results of this trial could position Shanghai Kanda Biotechnology Co., Ltd. favorably. Diligence should focus on the competitive advantages of KD6001, potential partnerships for further development, and the regulatory pathway ahead.

Matched by modality_normalized: protein therapy